Mesalazine liquid enema (DrugBank: Mesalazine)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
97 | Ulcerative colitis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00737789 (ClinicalTrials.gov) | November 2008 | 19/8/2008 | Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis. | Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis. | Ulcerative Colitis | Drug: Mesalazine slow-release granules;Drug: Mesalazine liquid enema | Ferring Pharmaceuticals | NULL | Completed | 18 Years | N/A | Both | 206 | Phase 3 | Belgium;France;Netherlands;United Kingdom |